top of page

Resources
Search


CCSS Response to Congressional Request for Information Regarding FDA Regulation of CBD
CCSS has submitted comments in response to the Congressional RFI on FDA regulation of CBD products in the marketplace. The key topics...
Aug 24, 2023


CCSS Statement on FDA Cannabinoid Pathway Framework Announcement
CCSS looks forward to working with Congress and FDA on a science-based approach to regulate non-drug CBD products, protecting consumer...
Feb 3, 2023


The Status and Risks of Unregulated Cannabinoid Products in the Marketplace
The cannabis plant contains more than a hundred chemical compounds known as cannabinoids, including the more commonly known cannabidiol...
Nov 14, 2022
bottom of page